ZYBERNO
Stock Report
Updated Aug 31, 2026

MAIA BIOTECHNOLOGY, INC. (MAIA)

Healthcare • NYSE

$1.31

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
MAIA BIOTECHNOLOGY, INC. (MAIA) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-211.1%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-3,369.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

MAIA BIOTECHNOLOGY, INC. (MAIA) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.31
Market Cap:$79.64M

Valuation Multiples (2)

P/B Ratio:3.85x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$52.04M

Price Action & Momentum (3)

Momentum Percentile:22 / 100
% of 52-Week High:41.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-126.3%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$47.01
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-43.0%
Latest Earnings Filed:2026-08-10
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.51x
Quick Ratio:4.51x
Cash Ratio:4.41x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-292,365.69x
Times Interest Earned:-292,365.69

Capital Structure (4)

Working Capital:21,979,479.00
Cash And Cash Equivalents:27,595,831.00
Long Term Debt:$0.00
Net Debt:-$27.60M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$28.95M

Bottom Line Performance (3)

-$26.85M
Income Before Tax:-$22.39M
Ebitda Ttm:-28,945,377.00

Operating Expenses (5)

Operating Expenses:28,945,377.00
R And D Expense:9,618,502.00
Sga Expense:11,541,687.00
Income Tax Expense:$2.34K
Interest Expense:58.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$28.24M
Current Assets:$28.24M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:7,565,161.00
Current Liabilities:6,257,892.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$20.68M
Retained Earnings:-$123.94M
Common Stock:150,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:2,838,652.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:723,915.00
C. Cash Flow Analysis

Operating Activities (2)

-$19.95M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$31.05M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:1,521,091.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.63
-$0.63
Earnings Per Share Ttm:-$0.44

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.26

Book Value & Capital (2)

Book Value Per Share:$0.34
Cash Per Share:0.45

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-8.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:MAIA
Company Name:MAIA BIOTECHNOLOGY, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:60.79M
Shares Outstanding Basic:60.79M
Shares Outstanding Diluted:60.79M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 21:31:26 UTC
Data Timestamp:2026-08-19T23:40:52.514089
Scroll to Top